This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b ...

Creyon Bio, Inc. ("Creyon") today announced a global licensing and multi-target research collaboration with Eli Lilly and Company ("Lilly") focused on the discovery, development and commercialization ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments ...

Fabrice Gritti, consultant scientist at Waters Corporation, spoke to LCGC International about the history of slalom ...

Many diseases are caused by a missing or defective copy of a single gene. For decades, scientists have been working on gene ...

"This partnership marks an important milestone for Creyon as we work to advance our RNA-targeted oligo therapy pipeline to the clinic for both rare and common diseases." “We are pleased to ...

The Boehringer Ingelheim Foundation is providing 600,000 Euros in funding for basic research into new approaches to the treatment of liver fibrosis and fatty liver hepatitis.

A research team has uncovered a previously unknown type of immune signaling molecule—a novel compound combining histidine and ...